COM-701 Drug Asset Due Diligence Report 2026

This COM-701 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether COM-701 can convert its Monoclonal antibody profile and CD112R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	COM-701 (query alias: COM-701)
Modality / target	Monoclonal antibody; CD112R; CD112R antagonists
Highest global status	Phase 1/2
Originator	Compugen, Inc.
Active developers	Compugen Ltd., Bristol Myers Squibb Co.

The MCP disease footprint includes Platinum-sensitive epithelial ovarian cancer, Recurrent ovarian cancer, Squamous Cell Carcinoma of Head and Neck. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06888921	Phase 1/2	Recruiting	60	Primary endpoint not disclosed in English source
NCT04570839	Phase 1/2	Completed	48	Primary endpoint not disclosed in English source
NCT04354246	Phase 1	Completed	94	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

MAIA-ovarian (NCT06888921) adaptive platform clinical trial to evaluate safety and efficacy of COM701 maintenance treatment in relapsed platinum-sensitive ovarian cancer (PSOC)

Phase 2; n=60; evaluation: Positive. Reported fields: PFS(12-month) = 60.0 % ; PFS(12-month) = 20.0 %

985 Triple blockade of DNAM-1axis with COM701(anti-PVRIG)+COM902(anti-TIGIT)+Pembrolizumab shows prelim antitumor activity in pts with platinum resistant ovarian cancer, interim results of phase I trial

Phase 1; n=25; evaluation: Positive. Reported fields: AE severity = Majority of AEs were of ≤2 grade in severity. No grade 4/5 events were reported. One grade 3 event of serious immune related encephalopathy was reported in one pt, which was resolving following treatment with steroids

Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.

Phase 1; n=20; evaluation: Positive. Reported fields: Adverse Event: treatment related AEs = Treatment related AEs were reported in 11/20 [55%] pts, the majority were ≤G2 7/20 [35%] with the most frequent TRAE of 4 pts each with ≤G2 fatigue, myalgia, 4/20 pts with G3 TRAE, there were no ≥G4 TRAEs

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

COM-701 addresses Platinum-sensitive epithelial ovarian cancer, Recurrent ovarian cancer, Squamous Cell Carcinoma of Head and Neck. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “target-level comparable: CD112R.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD112R records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2020-12-17	Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program	Preclinical	US$85.0M upfront; US$730.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Application of antisense oligonucleotide in preparation of medicine for treating breast cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO